Evidence map›Paper›PMID 8898378›Full record

ArticleMolecular medicine (Cambridge, Mass.)1996

A novel protease homolog differentially expressed in breast and ovarian cancer.

A Anisowicz, G Sotiropoulou, G Stenman, S C Mok, R Sager

Abstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

A AnisowiczDivision of Cancer Genetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
G Sotiropoulou
G Stenman
S C Mok
R Sager

Funding

ROLE OF NOVEL TUMOR SUPPRESSOR GENES IN BREAST CANCERR01CA057517 · NCI · DANA-FARBER CANCER INSTITUTE · PI SAGER, RUTH · 1992 to 1995
–
DIFFERENTIALLY EXPRESSED GENES IN PRIMARY BREAST CANCERR01CA061253 · NCI · DANA-FARBER CANCER INSTITUTE · PI PARDEE, ARTHUR B · 1993 to 1999
–
NCI NIH HHS CA57517NCI NIH HHS CA61253
6 · The paper itself

Abstract

backgroundUsing differential display (DD), we discovered a new member of the serine protease family of protein-cleaving enzymes, named protease M. The gene is most closely related by sequence to the kallikreins, to prostate-specific antigen (PSA), and to trypsin. The diagnostic use of PSA in prostate cancer suggested that a related molecule might be a predictor for breast or ovarian cancer. This, in turn, led to studies designed to characterize the protein and to screen for its expression in cancer. MATERIALS AND

methodsThe isolation of protease M by DD, the cloning and sequencing of the cDNA, and the comparison of the predicted protein structure with related proteins are described, as are methods to produce recombinant proteins and polyclonal antibody preparations. Protease M expression was examined in mammary, prostate, and ovarian cancer, as well as normal, cells and tissues. Stable transfectants expressing the protease M gene were produced in mammary carcinoma cells.

resultsProtease M was localized by fluorescent in situ hybridization analysis to chromosome 19q13.3, in a region to which other kallikreins and PSA also map. The gene is expressed in the primary mammary carcinoma lines tested but not in the corresponding cell lines of metastatic origin. It is strongly expressed in ovarian cancer tissues and cell lines. The enzyme activity could not be established, because of difficulties in producing sufficient recombinant protein, a common problem with proteases. Transfectants were selected that overexpress the mRNA, but the protein levels remained very low.

conclusionsProtease M expression (mRNA) may be a useful marker in the detection of primary mammary carcinomas, as well as primary ovarian cancers. Other medical applications are also likely, based on sequence relatedness to trypsin and PSA.

Indexed as

Gene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticKallikreinsAmino Acid SequenceAnimalsBaculoviridaeBase SequenceBreast NeoplasmsCell Line, TransformedDNA, ComplementaryFemaleGlutathione TransferaseHumansMaleMammary Glands, AnimalMolecular Sequence DataDNA, ComplementaryGlutathione TransferaseKallikreinsKLK6 protein, humanRecombinant Fusion ProteinsRNA, MessengerSerine Endopeptidases

Identifiers

PMID8898378
PMCPMC2230195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.